Aldeyra Therapeutics (ALDX) Operating Expenses (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Operating Expenses came in at $3.5 million in Q1 2026, down 65.98% YoY from $10.4 million in Q1 2025, and down 46.81% on a QoQ basis from $6.7 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Operating Expenses (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Operating Expenses data on file, last reported at $3.5 million in Q1 2026.
- Quarterly Operating Expenses fell 65.98% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.4 million (down 53.58% YoY) and the FY2025 annual result came in at $35.3 million, down 41.34% from the prior year.
- Operating Expenses fell to $3.5 million in Q1 2026, from $6.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $18.0 million in Q2 2024 to a low of $3.5 million in Q1 2026.
- A 5-year average of $12.0 million and a median of $10.4 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 171.87% — and 2026, when it plunged 65.98%.
- Tracing ALDX's Operating Expenses over 5 years: stood at $13.7 million in 2022, then plunged by 55.48% to $6.1 million in 2023, then soared by 171.87% to $16.6 million in 2024, then sank by 59.78% to $6.7 million in 2025, then slumped by 46.81% to $3.5 million in 2026.
- The last three Operating Expenses figures came in at $3.5 million (Q1 2026), $6.7 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 5.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.85 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 10.17 Mn |
| Mar 31, 2025 | 10.43 Mn |
| Dec 31, 2024 | 16.58 Mn |
| Sep 30, 2024 | 16.14 Mn |
| Jun 30, 2024 | 18.01 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 9.55 Mn |
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 16.80 Mn |
| Dec 31, 2022 | 13.70 Mn |
| Sep 30, 2022 | 14.78 Mn |
| Jun 30, 2022 | 17.71 Mn |
| Mar 31, 2022 | 16.48 Mn |
| Dec 31, 2021 | 15.40 Mn |
| Sep 30, 2021 | 15.44 Mn |